A new treatment for advanced prostate cancer that has stopped responding to abiraterone.
Official title: A Phase 2, Single-Arm Study of the CXCR1/2 Inhibitor SX-682 Plus Enzalutamide in Men with Abiraterone-Resistant Metastatic Castration Resistant Prostate Cancer (mCRPC)
Funded at Syntrix Biosystems, INC. · NIH-11114019 · Data updated 2026-11-12
This research is testing a new combination of medicines, SX-682 and enzalutamide, for men whose advanced prostate cancer has become resistant to abiraterone.
Quick facts
| Grant type | Sbir 2 grant |
|---|---|
| Study type | NIH-funded research |
| Funding institution | Syntrix Biosystems, INC. NIH-funded |
| Lab location | 1 site (Auburn, United States) |
| Project start | July 7, 2023 |
| Project end | June 30, 2027 |
| Funding year | 2025 |
| Award (this year) | $903,852 |
| NIH project number | 5R44CA278187-03 |
| Project ID | NIH-11114019 on NIH RePORTER |
Who could benefit from this research
✓Could help
Ideal candidates are men with metastatic castration-resistant prostate cancer whose disease has progressed despite prior treatment with abiraterone.
✕Less likely to help
Patients whose prostate cancer is still responding to abiraterone or who have not yet developed metastatic castration-resistant disease would not be the focus of this particular approach.
What this research studies
Prostate cancer is a serious concern for many men, especially when it spreads and becomes resistant to standard treatments like abiraterone. When this happens, current options are limited, and only a small percentage of men respond to further treatments like enzalutamide alone. This new approach combines enzalutamide with an investigational medicine called SX-682, which targets specific signals (CXCR1/2) that help prostate cancer grow and resist treatment. By blocking these signals, the hope is to make enzalutamide more effective and offer a new way to fight advanced prostate cancer.
Why it matters
Potential benefit: If successful, this new combination therapy could offer a much-needed treatment option for men with advanced prostate cancer that no longer responds to abiraterone, potentially extending their lives.
How similar studies have gone: While the specific combination is new, the targets (CXCR1/2) have been identified as important in prostate cancer resistance, suggesting a strong scientific basis for this novel approach.
Where this research is happening
-
Syntrix Biosystems, INC.
Auburn, United States Active
Researchers
- Principal investigator: Schuler, Aaron D — Syntrix Biosystems, INC.
- Study coordinator: Schuler, Aaron D
Related research
Other NIH-funded projects on the same topics.
-
Hyperactive methylation in a hard-to-treat prostate cancer subtype
Researchers are studying a newly identified methylation-heavy group of advanced prostate cancer to understand its biology and find clues for better treatments.
-
CXCR1/2 inhibitor plus enzalutamide for abiraterone-resistant metastatic prostate cancer
A phase 2 study tests whether adding SX-682 to enzalutamide helps men with advanced prostate cancer that no longer responds to abiraterone.
-
A newly discovered heavily methylated form of advanced prostate cancer
Researchers are looking at a newly found heavily methylated type of advanced prostate cancer to find markers and possible weak points for treatment in men with metastatic castration‑resistant prostate cancer.
-
Investigating a new treatment for men with advanced prostate cancer resistant to standard therapies
This study is looking for men with advanced prostate cancer who haven't had success with common treatments to see if a new drug called SX-682, when combined with enzalutamide, can help improve their treatment results.
-
Understanding how aggressive cell states emerge in castration-resistant prostate cancer
A research project aims to uncover the hidden cell states that help prostate cancer resist standard therapy and how these states arise early in tumor development.
-
Enhancer RNA CYP11A1-eRNA in castration-resistant prostate cancer
Researchers are testing a new RNA-based target, CYP11A1-eRNA, to see if blocking it can hamper the growth of castration-resistant prostate cancer in the lab and animal models.
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page.